Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis
Completed
- Conditions
- Amyotrophic Lateral Sclerosis
- Registration Number
- NCT02893605
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
This is a case-control study performed on a biological collection. The polymorphisms present on a pre-defined list of genes will be studied for 400 Amyotrophic Lateral Sclerosis (sporadic type) DNA samples and 400 control DNA samples.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
- The primary inclusion criterium is the same for that of the parent biological collection, i.e. the patients fulfill requirements for probable or definite Amyotrophic Lateral Sclerosis as defined by revised international criteria (Brooks et al 2000).
- Additionally, included patients were followed-up by doctors at the University Hospital of Montpellier, thus enabling verification of Amyotrophic Lateral Sclerosis criteria over time.
Exclusion Criteria
- The patient has a familial form of Amyotrophic Lateral Sclerosis (autosomic dominant or recessive types) with or without a mutation of one of the 3 genes known to be responsible for familial forms (SOD1, TARDBP, FUS). See Bender (1998).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The polymorphisms occurring on a pre-defined set of genes Day 0 (transversal study) The genes studied are: CYP2R1, CYP27A1, CYP3A4, CYP2J2, CYP27B1, CYP24A1, VDBP, VDR.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What role do CYP27B1 and VDR gene polymorphisms play in vitamin D metabolism and ALS progression?
How do vitamin D receptor polymorphisms correlate with Riluzole treatment outcomes in sporadic ALS?
Which SNPs in vitamin D-related genes predict ALS susceptibility or response to supplementation?
How do genetic variations in vitamin D metabolism influence adverse events in ALS patients?
Are there synergistic effects of vitamin D pathway modulators with Riluzole in ALS treatment?
Trial Locations
- Locations (1)
CHU de Montpellier - Hôpital Gui de Chauliac
🇫🇷Montpellier Cedex 5, France
CHU de Montpellier - Hôpital Gui de Chauliac🇫🇷Montpellier Cedex 5, France